Executive Summary & Recent Corporate Highlights [Second Quarter 2025 Business Updates](index=1&type=section&id=Second%20Quarter%202025%20Business%20Updates) Entrada Therapeutics advanced its DMD clinical pipeline, initiated new studies, progressed preclinical programs, and strengthened leadership [Clinical-Stage Development Pipeline](index=1&type=section&id=Clinical-Stage%20Development%20Pipeline) Entrada advanced multiple clinical programs for DMD, including ELEVATE-44-201 and ELEVATE-45-201, and progressed regulatory submissions and partnered DM1 and inherited retinal disease programs - First patient dosed in ELEVATE-44-201 (ENTR-601-44), a global Phase 1/2 multiple ascending dose (MAD) clinical study for ambulatory DMD patients amenable to exon 44 skipping, with data from Cohort 1 (6 mg/kg patient dose) anticipated in the **first half of 2026**[1](index=1&type=chunk)[2](index=2&type=chunk)[3](index=3&type=chunk) - Initiated ELEVATE-45-201 (ENTR-601-45), a global Phase 1/2 MAD clinical study for ambulatory DMD patients amenable to exon 45 skipping, on track to dose the first patient in **Q3 2025**, with data from Cohort 1 (5 mg/kg) expected in **mid-2026**[1](index=1&type=chunk)[2](index=2&type=chunk)[6](index=6&type=chunk) - Planned Phase 1b MAD clinical study of ENTR-601-44 (ELEVATE-44-102) in ambulatory and non-ambulatory adults living with DMD in the U.S. is on track to initiate in the **first half of 2026**[6](index=6&type=chunk) - Global regulatory applications for ENTR-601-50 are expected in **Q4 2025** and for ENTR-601-51 in **2026**[3](index=3&type=chunk)[6](index=6&type=chunk) - Vertex continues to enroll and dose the MAD portion of the global Phase 1/2 clinical trial of VX-670 for myotonic dystrophy type 1 (DM1), with enrollment and dosing expected to complete in **H1 2026**[6](index=6&type=chunk) - Advanced two inherited retinal disease programs into lead optimization, with the first clinical candidate nomination expected by **year-end 2025**[6](index=6&type=chunk) [Preclinical Pipeline](index=2&type=section&id=Preclinical%20Pipeline) The company generated positive preclinical data from programs outside its neuromuscular franchise, indicating a broader scope of therapeutic development - Generated positive preclinical data from programs outside its neuromuscular franchise, including new moieties[4](index=4&type=chunk) [Organizational Evolution](index=2&type=section&id=Organizational%20Evolution) Entrada strengthened its leadership team with strategic appointments to support accelerated clinical growth and other strategic priorities - Appointed Navid Khan, PhD, as Senior Vice President of Medical Affairs in **August 2025**[1](index=1&type=chunk)[6](index=6&type=chunk) - Appointed Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development in **July 2025**[1](index=1&type=chunk)[6](index=6&type=chunk) - Appointed Maha Radhakrishnan, MD, to the Company's Board of Directors in **June 2025**[6](index=6&type=chunk) [Cash Position](index=2&type=section&id=Cash%20Position) Entrada's cash, cash equivalents, and marketable securities decreased to $354.0 million as of June 30, 2025, but are projected to fund operations into Q2 2027 Cash, Cash Equivalents, and Marketable Securities | Metric | As of June 30, 2025 | As of Dec 31, 2024 | | :-------------------------------- | :------------------ | :----------------- | | Cash, cash equivalents and marketable securities | $354.0 million | $420.0 million | - Cash runway expected into **Q2 2027** based on current operating plans[1](index=1&type=chunk)[5](index=5&type=chunk) Detailed Second Quarter 2025 Financial Results [Collaboration Revenue](index=3&type=section&id=Collaboration%20Revenue) Collaboration revenue significantly decreased in Q2 2025 to $2.0 million from $94.7 million in Q2 2024, primarily due to the substantial completion of research activities for the VX-670 collaboration Collaboration Revenue Overview | Period | 2025 (Q2) | 2024 (Q2) | Change | | :------- | :---------- | :---------- | :----- | | Revenue | $2.0 million | $94.7 million | -$92.7 million | - The decrease was primarily attributable to the substantial completion of the collaboration research plan activities associated with VX-670[7](index=7&type=chunk) [Operating Expenses](index=3&type=section&id=Operating%20Expenses) Total operating expenses increased to $48.8 million in Q2 2025 from $41.3 million in Q2 2024, driven by higher R&D costs for DMD programs and increased personnel costs Total Operating Expenses | Period | 2025 (Q2) | 2024 (Q2) | Change | | :------- | :---------- | :---------- | :----- | | Total operating expenses | $48.8 million | $41.3 million | +$7.5 million | [Research & Development (R&D) Expenses](index=3&type=section&id=Research%20%26%20Development%20(R%26D)%20Expenses) R&D expenses increased to $37.9 million in Q2 2025 from $32.0 million in Q2 2024, primarily due to additional costs for DMD programs and higher personnel costs Research & Development Expenses | Period | 2025 (Q2) | 2024 (Q2) | Change | | :------- | :---------- | :---------- | :----- | | R&D Expenses | $37.9 million | $32.0 million | +$5.9 million | - The increase was primarily driven by additional costs incurred related to the Company's DMD programs, as well as higher personnel costs (including non-cash, stock-based compensation)[8](index=8&type=chunk) [General & Administrative (G&A) Expenses](index=3&type=section&id=General%20%26%20Administrative%20(G%26A)%20Expenses) G&A expenses rose to $10.9 million in Q2 2025 from $9.2 million in Q2 2024, mainly due to increased personnel costs, including non-cash stock-based compensation General & Administrative Expenses | Period | 2025 (Q2) | 2024 (Q2) | Change | | :------- | :---------- | :---------- | :----- | | G&A Expenses | $10.9 million | $9.2 million | +$1.7 million | - The increase was primarily due to higher personnel costs (including non-cash, stock-based compensation)[9](index=9&type=chunk) [Net Income (Loss)](index=3&type=section&id=Net%20Income%20(Loss)) Entrada reported a net loss of $(43.1) million for Q2 2025, a significant decline from a net income of $55.0 million in Q2 2024, resulting in a basic net loss per share of $(1.04) Net Income (Loss) Summary | Period | 2025 (Q2) | 2024 (Q2) | Change | | :------- | :---------- | :---------- | :----- | | Net Income (Loss) | $(43.1) million | $55.0 million | -$98.1 million | | Net (Loss) Income per share, basic | $(1.04) | $1.61 | -$2.65 | [Condensed Consolidated Financial Statements (Unaudited)](index=5&type=section&id=Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The unaudited statements of operations show a significant decrease in collaboration revenue and an increase in operating expenses, leading to a net loss for both the three and six months ended June 30, 2025, compared to net income in the prior year periods Condensed Consolidated Statements of Operations (in millions of dollars, except per share data) | | Three Months Ended June 30, | | Six Months Ended June 30, | | :-------------------------------- | :---------- | :---------- | :---------- | :---------- | | | **2025** | **2024** | **2025** | **2024** | | Collaboration revenue | $1.95 | $94.69 | $22.51 | $153.81 | | Operating expenses: | | | | | | Research and development | 37.88 | 32.04 | 69.95 | 60.64 | | General and administrative | 10.92 | 9.24 | 21.20 | 18.64 | | Total operating expenses | 48.80 | 41.27 | 91.15 | 79.28 | | (Loss) income from operations | (46.85) | 53.42 | (68.64) | 74.54 | | Other income: | | | | | | Interest and other income | 3.92 | 4.37 | 8.37 | 8.58 | | Total other income | 3.92 | 4.37 | 8.37 | 8.58 | | (Loss) income before provision for income taxes | (42.93) | 57.79 | (60.27) | 83.12 | | Provision for income taxes | 0.18 | 2.76 | 0.18 | 4.59 | | Net (loss) income | $(43.10) | $55.03 | $(60.45)

Clinical Programs & Pipeline - Entrada Therapeutics expects to have four active clinical-stage programs by the end of 2025[7, 17] - ENTR-601-44 is currently dosing patients in the UK and EU and is authorized in the US[7] Data from Cohort 1 of the ELEVATE-44-201 study is expected in the first half of 2026[3, 38] - ENTR-601-45 patient study is currently enrolling in the UK and EU, with first patient dosing expected in Q3 2025 and initial data from the first patient cohort expected in mid-2026[3, 7, 41] - Global regulatory filings for ENTR-601-50 are on track for submission in Q4 2025, and for ENTR-601-51 in 2026[3, 7, 42] - Vertex's DM1 program, VX-670, has an ongoing MAD portion of its global Phase 1/2 study to evaluate safety and efficacy, with completion of enrollment and dosing expected in H1 2026[7, 18] Financial Position - The company reports a cash balance of approximately $354 million as of June 30, 2025[8] - This cash balance is expected to provide a runway into Q2 2027[3, 8, 60] EEV Platform & Technology - The company's Endosomal Escape Vehicle (EEV) technology achieves approximately 50% endosomal escape, compared to a standard of approximately 2%[12] - EEV therapies demonstrate approximately 90% cellular uptake[13] ENTR-601-44 Phase 1 Data - The ENTR-601-44-101 study showed strong clinical safety up to 6 mg/kg, with no treatment-related adverse events reported[21, 22] - Favorable target exposure and engagement were observed at 6 mg/kg, with statistically significant exon skipping versus placebo[30, 33]

Company Overview - Entrada Therapeutics, Inc. (TRDA) shares increased by 5.6% to $6.64 in the last trading session, following a period of 11.5% loss over the past four weeks [1][2] - The rise in stock price is linked to growing investor optimism regarding the company's lead oligonucleotide programs aimed at treating Duchenne muscular dystrophy for specific exon skipping [2] Financial Performance - The company is projected to report a quarterly loss of $0.86 per share, reflecting a year-over-year decline of 155.5% [2] - Expected revenues for the upcoming quarter are $8.87 million, which is a significant decrease of 90.6% compared to the same quarter last year [2] Earnings Estimates and Stock Trends - The consensus EPS estimate for Entrada Therapeutics has remained unchanged over the last 30 days, indicating a lack of upward revisions that typically support stock price increases [4] - Historical data suggests that trends in earnings estimate revisions are closely correlated with short-term stock price movements, highlighting the importance of monitoring these estimates [3] Industry Context - Entrada Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where another company, Bicycle Therapeutics PLC (BCYC), experienced a slight decline of 0.1% to $8.51, but has seen a 21.2% return over the past month [5] - Bicycle Therapeutics has a consensus EPS estimate of -$0.95 for its upcoming report, which is a 23.4% decrease from the previous year [6]

Summary of Entrada Therapeutics (TRDA) 2025 Conference Call Company Overview - **Company**: Entrada Therapeutics (TRDA) - **Focus**: Development of intracellular therapeutics targeting neuromuscular diseases, specifically Duchenne muscular dystrophy (DMD) and myotonic dystrophy type one (DM1) [2][7] Key Clinical Programs - **Active Clinical Programs**: By the end of 2025, the company expects to have four active clinical programs [2] - **Duchenne Muscular Dystrophy (DMD) Franchise**: - **ENTR-601-44**: Clinical studies authorized in the UK, US, and EU; currently enrolling [3] - **ENTR-601-45**: Regulatory clearance obtained; clinical trial enrollment to begin [3] - **ENTR-601-50**: Regulatory submission expected in the second half of 2025 [4] - **Myotonic Dystrophy Type One (DM1)**: Collaboration with Vertex on VX-670; ongoing global study with 26 clinical sites [5] Financial Position - **Cash Position**: Approximately $383 million on the balance sheet, providing a cash runway into Q2 2027 [6][37] - **Importance of Cash**: Financial stability allows the company to navigate critical clinical data points and potential inflection points [6][37] Therapeutic Approach - **Intracellular Targets**: 75% of disease-causing targets are intracellular, which presents significant opportunities for the company [8][11] - **Endosomal Escape Vehicles (EEVs)**: Utilization of cyclic cell-penetrating peptides to enhance cellular uptake and improve therapeutic delivery [8][9] Clinical Data and Safety - **Phase 1 Study for ENTR-601-44**: - Conducted with 32 subjects (24 active, 8 placebo); demonstrated strong clinical safety with no treatment-related adverse effects [17][19] - Dose-dependent increase in plasma concentration observed, indicating a broad therapeutic window [21] - **Future Studies**: Plans to run a global two-part study for ENTR-601-44 and ENTR-601-45, focusing on safety, tolerability, and efficacy [28][30] Market Opportunity - **Duchenne Muscular Dystrophy**: Over 40,000 individuals affected in the US and Europe, highlighting a significant unmet clinical need [27] - **Pipeline Expansion**: Potential to explore ocular programs and other diseases beyond neuromuscular conditions [34][37] Conclusion - **Outlook**: The company is positioned for a busy 2025 and beyond with multiple clinical studies and a strong financial foundation, aiming to address significant unmet needs in neuromuscular diseases and potentially expand into other therapeutic areas [35][37]

Company Overview - Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible [4] - The company utilizes its proprietary Endosomal Escape Vehicle (EEV™) technology to enhance the intracellular delivery of therapeutics, aiming to improve therapeutic indices across various diseases [4] Recent Developments - The company announced the appointment of Dr. Maha Radhakrishnan to its Board of Directors, which is expected to bolster its clinical momentum, particularly in the Duchenne muscular dystrophy franchise [1][2] - Dr. Radhakrishnan brings extensive experience in global drug development, having previously held senior roles at Biogen and Sanofi, which will be instrumental as Entrada advances its clinical-stage portfolio [3] Clinical Focus - Entrada is advancing multiple patient-focused clinical trials for its Duchenne muscular dystrophy programs throughout the year, with promising Phase 1 safety and target engagement data [2][3] - The company is developing lead oligonucleotide programs targeting exon 44, 45, 50, and 51 skipping for the treatment of Duchenne muscular dystrophy [4]

Company Overview - Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of medicines that target intracellular mechanisms previously deemed inaccessible [3] - The company utilizes its proprietary Endosomal Escape Vehicle (EEV™) technology to enhance the intracellular delivery of therapeutics, aiming to improve therapeutic indices across various organs and tissues [3] - Entrada is advancing a diverse portfolio of RNA- and protein-based programs, particularly targeting neuromuscular and ocular diseases, with lead programs aimed at treating Duchenne muscular dystrophy [3] Recent Developments - On June 1, 2025, Entrada Therapeutics granted a total of 23,820 restricted stock units (RSUs) to six newly-hired non-executive employees as part of its 2025 Inducement Equity Plan [1] - The RSUs will vest incrementally, with one-fourth vesting on the one-year anniversary of the vesting commencement date, followed by quarterly vesting of 6.25% thereafter [2] - The inducement grants were approved by the Compensation Committee of the Board of Directors to incentivize new employees in accordance with Nasdaq Listing Rule 5635(c)(4) [1][2]

Financial Position - The company has an accumulated deficit of $146.7 million as of March 31, 2025, and expects to continue generating operating losses and negative cash flows for the foreseeable future[95]. - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $382.5 million, which is projected to fund operations into the second quarter of 2027[99]. - Cash, cash equivalents, and marketable securities totaled $382.5 million as of March 31, 2025, with an accumulated deficit of $146.7 million[125]. - Net cash used in operating activities was $38.5 million for Q1 2025, compared to $25.5 million in Q1 2024, driven by a net loss and changes in operating assets and liabilities[128][129]. - The company anticipates that its cash resources will be sufficient to fund operations into the second quarter of 2027 based on current operating plans[134]. Revenue and Expenses - Collaboration revenue decreased to $20.6 million for the three months ended March 31, 2025, from $59.1 million in the same period of 2024, primarily due to a $38.7 million cumulative catch-up adjustment in 2024[118]. - Total operating expenses increased to $42.3 million in Q1 2025 from $38.0 million in Q1 2024, with research and development expenses rising by $3.5 million to $32.1 million[117][120]. - Net loss for the three months ended March 31, 2025, was $17.3 million, compared to a net income of $23.5 million in the same period of 2024, reflecting a change of $40.8 million[117]. - General and administrative expenses increased to $10.3 million in Q1 2025 from $9.4 million in Q1 2024, primarily due to increased personnel costs[121]. - Total interest and other income increased to $4.4 million in Q1 2025 from $4.2 million in Q1 2024, driven by higher interest income from investments[122]. Clinical Development and Strategic Plans - The company plans to initiate three clinical trials by year-end 2025 for its DMD franchise, including ENTR-601-44, ENTR-601-45, and ENTR-601-50[92]. - The company received authorization from the FDA to lift the clinical hold on ENTR-601-44 and plans to initiate a Phase 1b MAD clinical study in adult DMD patients in the first half of 2026[93]. - A new strategic plan was announced on April 29, 2025, focusing on DMD clinical candidates and reducing the workforce by approximately 20%[93]. - The company expects to incur significant expenses related to developing internal commercialization capabilities if any therapeutic candidates receive regulatory approval[95]. - The company has positive preclinical data for programs outside its neuromuscular franchise and plans to share its first clinical candidate in ocular disease later in 2025[94]. Growth Strategy and Market Risks - The company is focused on acquiring or in-licensing products, intellectual property, and technologies as part of its growth strategy[141]. - The company has added operational, financial, and management information systems to support product development[141]. - The company qualifies as an "emerging growth company" under the JOBS Act, allowing for delayed adoption of new accounting standards until certain revenue thresholds are met[140]. - The company will no longer qualify as a "smaller reporting company" effective December 31, 2024, impacting its reporting requirements[143]. - The company is exposed to interest rate market risk, but changes in interest rates have not materially impacted its financial position to date[145][146]. - Inflation has not had a material effect on the company's results of operations during the periods presented[147]. - The company is exposed to foreign currency exchange risk but has not experienced material effects from fluctuations to date[150]. Operational Adjustments - The company intends to implement a new strategic plan aimed at achieving expected cost savings, including a reduction in force[141]. - The company has not sold any shares under the 2023 ATM Program, which allows for sales of up to $150.0 million in common stock[126]. - The company has entered into license agreements with no material changes to commitments and contingencies as of March 31, 2025[139]. - The company may take advantage of exemptions under the JOBS Act, including reduced disclosure about executive compensation arrangements[149].

Eton Pharmaceuticals, Inc. (ETON) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, ...